替格瑞洛联合匹伐他汀及阿司匹林治疗老年脑梗死的临床研究OA
Clinical trial on the treatment of elderly cerebral infarction with ticagrelor combined with pitavastatin and aspirin
目的 观察阿司匹林肠溶片联合替格瑞洛片及匹伐他汀钙片治疗老年脑梗死的临床疗效及安全性.方法 将本院收治的老年脑梗死患者分为试验组和对照组,均给予相同的基础对症治疗(阿司匹林肠溶片等),对照组给予匹伐他汀钙片(口服,每次7 mg,每天1次)治疗,试验组给予替格瑞洛片(每次90 mg,每天2次)联合匹伐他汀钙片(口服,每次7 mg,每天1次)治疗,均连续治疗3周.比较2组的临床疗效、美国国立卫生研究院卒中量表(NIHSS)评分、日常生活活动量表(ADL)评分、血液流变学、血清神经元特异性烯醇化酶(NSE)、中枢神经特异性蛋白(S100β)、超敏C-反应蛋白(hs-CRP)、白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)水平,并进行安全性分析.结果 共筛选102例,2组均无脱落病例,最终试验组和对照组各纳入51例.治疗后,试验组和对照组的临床有效率分别为90.20%(46例/51例)和74.51%(38例/51例),NIHSS评分分别为(6.61±2.19)和(11.47±3.22)分,ADL评分分别为(78.25±8.02)和(70.82±7.69)分,全血高切黏度分别为(4.21±0.69)和(5.86±1.13)mPa·s,全血低切黏度分别为(8.28±2.32)和(10.74±2.83)mPa·s,血浆黏度分别为(1.21±0.22)和(1.66±0.34)mPa·s,血细胞比容分别为(36.28±4.75)%和(39.62±5.08)%,血清NSE水平分别为(16.57±2.92)和(23.54±3.13)μg·L-1,血清 S100β 水平分别为(0.52±0.12)和(0.86±0.17)μg·L-1,血清 hs-CRP 水平分别为(8.29±1.09)和(12.06±1.54)mg·L-1,IL-6 水平分别为(13.47±1.55)和(19.21±2.02)ng·L-1,TNF-α 水平分别为(24.23±2.56)和(30.32±3.43)ng·L-1,上述指标在2组间比较,在统计学上差异均有统计学意义(均P<0.05).试验组的药物不良反应包括恶心呕吐,消化不良和肝肾功能异常;对照组包括恶心呕吐,消化不良,心律失常和肝肾功能异常.试验组和对照组的药物不良反应总发生率分别为9.80%(5例/51例)和7.84%(4例/51例),在统计学上差异无统计学意义(P>0.05).结论 用替格瑞洛片联合匹伐他汀钙片、阿司匹林肠溶片治疗老年脑梗死具有较好临床疗效,可以促进神经功能及自理能力恢复,改善血液流变学,减少炎症反应,且安全性较好.
Objective To explore the clinical efficacy and safety of aspirin enteric-coated tablets combined with ticagrelor tablets and pitavastatin calcium tablets in the treatment of cerebral infarction in the elderly.Methods Elderly patients admitted to our hospital with cerebral infarction were divided into treatment group and control group,they were given the same basic symptomatic treatment(aspirin enteric-coated tablets,etc.).The control group was treated with pitavastatin calcium tablets(oral administration,7 mg each time,once a day),while the treatment group was treated with ticagrelor tablets(90 mg each time,twice a day)combined with pitavastatin calcium tablets(oral,7 mg per time,once daily)for 3 weeks.The clinical efficacy,National Institutes of Health Stroke Scale(NIHSS)score,activities of daily living scale(ADL)score,hemorheology,serum neuron-specific enolase(NSE),central nerve-specific protein(S100β),high-sensitivity C-reactive protein(hs-CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)levels were compared between the two groups,and safety analysis was conducted.Results A total of 102 cases were screened.There was no shedding cases were found in the two groups.Ultimately,both treatment and control groups comprised 51 cases.Following treatment,the clinical effective rates of the two groups were 90.20%(46 cases/51 cases)and 74.51%(38 cases/51 cases),respectively;the NIHSS scores were(6.61±2.19)and(11.47±3.22)points,respectively;the ADL scores were(78.25±8.02)and(70.82±7.69)points,respectively;the whole blood high shear viscosity was(4.21±0.69)and(5.86±1.13)mPa·s-1,respectively;the whole blood low shear viscosity was(8.28±2.32)and(10.74±2.83)mPa·s-1,respectively;the plasma viscosity was(1.21±0.22)and(1.66±0.34)mPa·s-1,respectively;the hematocrit was(36.28±4.75)% and(39.62±5.08)%,respectively;the serum NSE levels were(16.57±2.92)and(23.54±3.13)μg·L-1,respectively;the serum S100β levels were(0.52±0.12)and(0.86±0.17)μg·L-1,respectively;the serum hs-CRP levels were(8.29±1.09)and(12.06±1.54)mg·L-1,respectively;the IL-6 levels were(13.47±1.55)and(19.21±2.02)ng·L-1,respectively.The levels of TNF-α were(24.23±2.56)and(30.32±3.43)ng·L-1,respectively.There were statistically significant differences between the two groups in the above indexes(all P<0.05).The adverse drug reactions in treatment group included nausea,vomiting,indigestion,abnormal liver and kidney function;those in control group included nausea,vomiting,indigestion,arrhythmia,abnormal liver and kidney function.The overall incidence rates of adverse drug reactions were 9.80%(5 cases/51 cases)in treatment group and 7.84%(4 cases/51 cases)in control group,with no statistically significant difference(P>0.05).Conclusion The treatment of elderly cerebral infarction with ticagrelor tablets combined with pitavastatin calcium tablets and enteric-coated aspirin tablets has a good clinical effect.It can promote the recovery of neurological function and self-care ability,improve hemorheology,reduce inflammatory response,and has good safety.
罗力亚;刘翠青;耿丽洁;刘姗姗
河北省第八人民医院老年科,河北 石家庄 050000河北省第八人民医院老年科,河北 石家庄 050000河北省第八人民医院老年科,河北 石家庄 050000河北省第八人民医院老年科,河北 石家庄 050000
医药卫生
替格瑞洛片匹伐他汀钙片老年脑梗死血液流变学超敏C-反应蛋白中枢神经特异性蛋白
ticagrelor tabletpravastatin calcium tabletelderly cerebral infarctionhemorheologyhigh sensitivity C-reactive proteincentral nervous system specific protein
《中国临床药理学杂志》 2026 (13)
1825-1830,6
河北省2018年度医学科学研究重点课题计划项目基金资助项目(20180685)
评论